

Ocrelizumab

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Ocrelizumab

ATC codes

[L04AG08](#)

Medicine type

Biological agent

EML status history

Application rejected in 2019 ([TRS 1021](#)) for [Relapsing-remitting multiple sclerosis](#)

Application rejected in 2023 ([TRS 1049](#)) for [Multiple sclerosis](#)

Wikipedia

[Ocrelizumab](#)

DrugBank

[Ocrelizumab](#)

Recommendations

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
- Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

[Relapsing-remitting multiple sclerosis](#) [Multiple sclerosis](#)